菜单
  • 1-1. What are the ways to collaborate on innovative targets?

    Regarding innovative targets, we mainly cooperate in following ways: Service, joint development, targeted pre-research and incubation, etc., and both parties own corresponding rights and interests according to the proportion of project risks and investment. 

  • 1-2. Regarding some common molecular targets used as tools in the market, is it possible to transfer them at a low price?

    Regarding project transfer, we have a standard business strategy that is in line with the market valuation and accounting principles; regarding molecules used as tools, we only transfer part of the development rights or those in a single field in general, instead of transferring or authorizing all rights and interests, on a case-by-case basis.

  • 2. How to handle projects with same target from different clients?

    1) Typically, we only cooperate with one customer on each target with exclusivity agreement. 
    2) We will not cooperate with other companies until the exclusivity agreement on the same target expires, and no materials, intermediate products, or final results of the previous project will be used in other companies' projects. 
    3) Regarding projects undergoing separate library screening, customers generally do not inform the target, so we will select 

  • 3. Is the format of bi-specific antibody (bsAb) provided by Sanyou Bio related to the IP of other companies?

    Sanyou's IP Department has conducted patent retrieval and analysis of its conventional bsAb formats, and the results show that there is no patent infringement risk for the bsAb formats. If the customers need other formats, it is recommended that they engage a third-party professional organization to conduct a Freedom-To-Operate (FTO) analysis to confirm whether there are patent infringement risks.

  • 4. How do you ensure that screened antibody sequences and those delivered by other projects do not involve patent conflicts?

    Please emphasize that we will deliver all new sequences different from those of previous customers. If the client is very concerned about the patent, suggest them to: 
    1) Entrust patent analysis and retrieval to a third-party professional organization  to confirm the novelty of the sequence and FTO; 
    2) Ask our IP Department  to conduct patent analysis and retrieval to confirm the novelty of the sequence and FTO. This is a time-consuming job, and an additional fee is required referring to the fees charged by a third-party professional organization.